A COMPARATIVE STUDY ON MONOTHERAPY AND COMBINATION THERAPY OF PANTOPRAZOLE WITH PREGABALIN AGAINST SURGICAL ESOPHAGITIS
The objective of this study was to evaluate the effect of pantoprazole and pregabalin on experimental esophagitis in albino rats. The groups of rats fasted for 24 hours and were subjected to pylorus and forestomach ligation. Rats of different groups received normal saline (3 ml/kg, po; sham control), pantoprazole (30 mg/kg, po), pregabalin (30 mg/kg, po) and their combinations along with a parallel toxic control group. Animals were sacrificed after 8 h and evaluated for the gastric pH, total acidity, free acidity and esophagitis index. The morphological changes were scrutinized by digital microscopy. The beneficial effect of pantoprazole and pregabalin against GERD could be attributed to the anti-secretory action of pantoprazole and reduction in the tracheal lower esophageal sphincter release rate by pregabalin. Combination therapy of gamma-aminobutyric acid derivative promotes proton pump inhibitor based healing of reflux esophagitis in animal model.
Keywords: Esophagitis, Pantoprazole, Pregabalin, Pylorus ligation, Gamma-aminobutyric acid.
2. Wang YK, Hsu WH, Wang SSW, Current pharmacological management of gastroesophageal reflux disease, Gastroenterology Research and Practice, 2013; 12(5):535-540.
3. Tripathy S, Afrin R, Herbal treatment alternatives for peptic ulcer disease, Journal of Drug Delivery & Therapeutics. 2016; 6(3):27-33
4. Lee Y, Yen AM, Tai JJ, Chang S, Lin J, Chiu H, The effect of metabolic risk factors on the natural course of gastro-oesophageal reflux disease, Gut, 2008; 58(2):174–181.
5. Kindt S, Tertychnyy A, Dehertogh G, Geboes K, Tack J, Intestinal immune activation in presumed post-infectious functional dyspepsia, Neurogastroenterology and Motility, 2009; 21(8):832–856.
6. Dent J, El Serag HB, Wallander MA, Johansson S, Epidemiology of gastroesophageal reflux disease: a systematic review, Gut, 2005; 54(5):710–717.
7. Boeckxstaens GEE, The pathophysiology of gastro-oesophageal reflux disease, Alimentary Pharmacology & Therapeutics, 2007; 26(2):149-160.
8. Wylie JD, John D, Walter JH, James FH, Richard H, Patel GK, Mark S, Mechanisms of Gastroesophageal Reflux in Patients with Reflux Esophagitis, The New England Journal of Medicine, 1982; 307 (25):1547-1552.
9. Baehr PH, McDonald GB, Esophageal infections, risk factors, presentation, diagnosis, and treatment, Gastroenterology, 1994; 106 (2):509-532.
10. Vaughan TL, Kristal AR, Blount PL, Levine DS, Galipeau PC, Prevo LJ, Sanchez CA, Rabinovitch PS, Reid BJ, Nonsteroidal anti-inflammatory drug use, body mass index, and anthropometry in relation to genetic and flow cytometric abnormalities in Barrett's esophagus, Cancer Epidemiology Biomarkers and Prevention, 2002; 11(8):745-52.
11. Corley DA, Kubo A, Levin TR, Block G, Habel L, Zhao W, Leighton P, Quesenberry C, Rumore GJ, Buffler PA, Abdominal obesity and body mass index as risk factors for Barrett's esophagus, Gastroenterology, (2007; 133(1):34-41.
12. Pereira RS, Regression of gastro-esophageal reflux disease symptoms using dietary supplementation with melatonin, vitamins and amino acids: comparison with omeprazole, Journal of Pineal Research, 2006; 41(3):195–200.
13. Scarpignato C, Hunt RH, PPI: the beginning of the end or the end of the beginning?, Current Opinion in Pharmacology, 2008; 8(6): 677–684.
14. Azizollahi HR, Rafeey M, Efficacy of proton pump inhibitors and H2 blocker in the treatment of symptomaticgastroesophageal reflux disease in infants, Korean Journal of Pediatrics, 2016; 59(5):226-30.
15. Fry LC, Monkemiiler K, Malfertheiner P, Functional heartburn, non-erosive reflux disease and reflux esophagitis are all distinct conditions: a debate, Current Treatment Options in Gastroenterology, 2007; 10(4):305-11.
16. Fox RK, Muniraj T, Pharmacologic Therapies in Gastrointestinal Diseases, Medical Clinics of North America, 2016; 100(4):827-50.
17. Fock KM, Tally N, Hunt R, Fass R, Report of Asia-Pacific consensus on the gastroesophageal reflux disease, treatment of gastroesophageal reflux disease clinical cornerstone 1 GERD 1, Journal of Gastroenterology and Hepatology, 2004; 19(4):357-367.
18. Lidmus L, Lehman A, Cheklin H, Dent J, Holloway RH, Control of transiet lower esophagus spincture relaxations and reflux by the GABA (B) agonist baclofen in normal subjects, Gastroenterology, 2000; 118(1):7–13.
19. Stoddard CJ, Randomized clinical trial of laparoscopic versus open fundoplication for gastro-oesophageal reﬂux disease, British Journal of Surgery, 2004; 91(8):975–982.
20. Sullivan JS, Sundaram SS, Gastroesophageal reflux, Pediatrics Review, 2012; 33(6):243-53.
21. Lidmus L, Lehman A, Cheklin H, Dent J, Holloway RH, Control of transiet lower esophagus spincture relaxations and reflux by the GABA(B) agonist baclofen in normal subjects. Gastroenterology 2000; 118:7–13.
22. White RJ, Morris GP, Paterson WG, Impairment of deglutition reflex by acid-induced esophageal mucosal injury, Digestive Diseases and Sciences, 2001; 46(4):802–807.
23. Renu RG, Kaithwas PWR, Saraf SA, Effect of Linum Usittatisumum fixed oil on experimental esophagitis in rats, Acta Gastroenterlogica Belgica, 2012; 75(3):331–335.
24. Kaithwas G, Majumdar DK, Evaluation of antiulcer and antisecretory potential of L. usitatisimum fixed oil and possible mechanism of action, Inflammopharmacology, 2010; 18(3):137–145.
25. Ohkawa H, Ohishi N, Yagi K, Assay of lipid peroxide in animal tissues by thiobarbituric acid reaction, Annals of Biochemistry, 1979; 95(2):351–8.
26. Sedlak J, Lindsay RH, Estimation of total protein and non-protein bound sulphahydryl groups in tissue with Ellman’s reagent, Annals of Biochemistry, 1968; 25(1): 192–205.
27. Ellman GL, Tissue sulphydryl groups, Archives of Biochemistry and Biophysics, 1995; 82(1):70–7.
28. Pareta S, Kodati D, Patra KC, Antiulcer activity of ethanolic extract of Buchanania lanzanSpreg. Roots, Annals of Biological Research, 2010; 1(4):234-239.
29. Khinchi P, Saha S, Saraf SA, Kaithwas G, Combination therapy of gamma-aminobutyric acid derivative promotes proton pump inhibitors based healing of reflux esophagitis in animal model, Pharmacological Reports, 2014; 66(1):165-168.
30. Yusuf S, Nok AJ, Ameh DA, Adelaiye AB, Balogun EO, Quantitative changes in gastric mucosal glycoproteins: effect of cholinergic agonist and vagal nerve stimulation in the rat, Neurogastroenterology and Motility, 2004; 16(5):613– 619.
31. Farhadi A, Fields J, Banan A, Keshavarzian A, Reactive oxygen species: are they involved in the pathogenesis of GERD, Barrett’s esophagus, and the Latter’s progression toward esophageal cancer, American Journal of Gastroenterology, 2002; 97(1):22–26.
32. Kahrilas PJ, Review article: gastro-oesophageal reflux disease as a functional gastrointestinal disorder, Alimentary Pharmacology and Therapeutics, 2004; 20(7):50-55.
33. Kaithwas G and Majumdar DK, In vitro antioxidant and in vivo antidiabetic, antihyperlipidemic activity of linseed oil against streptozotocin-induced toxicity in albino rats, European Journal of Lipid Science and Technology, 2012; 114 (11):1237–1245.
34. Stein HJ, Hinder RA, Oosthuizen MMJ, Gastric mucosal injury caused by hemorrhagic shock and reperfusion: protective role of the antioxidant glutathione, Surgery, 1990; 108(2) 467–474.
35. Stein HJ, Oosthuizen MMJ, Hinder RA, Lamprechts H, O’Brien P, Effect of verapamil on hepatic ischemia/reperfusion injury, American Journal of Surgery, 1993; 165(1):96–100.
36. Scholten T, Long-term management of gastroesophageal reflux disease with pantoprazole, Therapeutics and Clinical Risk Management, 2007; 3(2): 231–243.
37. Suwannaphet W, Meeprom A, Yibchok-Anun S, Adisakwattana S, Preventive effect of grape seed extract against highfructose diet-induced insulin resistance and oxidative stress in Rats, Food and Chemical Toxicology, 2010; 48(7):1853–1857.
38. Kaithwas G, Dubey K, Pillai KK, Effect of Aloe vera (Aloe barbadensis Miller) gel on doxorubicin-induced myocardial oxidative stress and calcium overload in albino rats, Indian Journal of Experimental Biology, 2011; 49(4):260–268.
39. Rao CV, Vijayakumar M, Effect of quercetin, flavonoids and a-tocopherol, an antioxidant vitamin on experimental reflux esophagitis in rats. European Journal of Pharmacology 2008; 589:233–8. 40.
40. Kunsch S, Neesse A, Linhart T et al., Prospective evaluation of duodenogastroesophageal reflux in gastroesophageal reflux disease patients refractory to proton pump inhibitor therapy, Digestion, 2012; 86(4):315–322.
41. Shin JM, Sachs G, Pharmacology of proton pump inhibitors, Current Gastroenterology Report, 2008; 10(6):528–534.
42. Dent J, El Serag HB, Wallander MA, Johansson S, Epidemiology of gastroesophageal reflux disease: a systematic review, Gut, 2005; 54(5):710–7.
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0). that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).